ATE393625T1 - Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen - Google Patents
Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifenInfo
- Publication number
- ATE393625T1 ATE393625T1 AT04740032T AT04740032T ATE393625T1 AT E393625 T1 ATE393625 T1 AT E393625T1 AT 04740032 T AT04740032 T AT 04740032T AT 04740032 T AT04740032 T AT 04740032T AT E393625 T1 ATE393625 T1 AT E393625T1
- Authority
- AT
- Austria
- Prior art keywords
- prevention
- treatment
- hydroxy tamoxifen
- excessive scaring
- excessive
- Prior art date
Links
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 230000037390 scarring Effects 0.000 abstract 3
- 208000032544 Cicatrix Diseases 0.000 abstract 1
- 208000002260 Keloid Diseases 0.000 abstract 1
- 206010023330 Keloid scar Diseases 0.000 abstract 1
- 230000001969 hypertrophic effect Effects 0.000 abstract 1
- 210000001117 keloid Anatomy 0.000 abstract 1
- 231100000241 scar Toxicity 0.000 abstract 1
- 230000037387 scars Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47661803P | 2003-06-09 | 2003-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE393625T1 true ATE393625T1 (de) | 2008-05-15 |
Family
ID=33551623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04740032T ATE393625T1 (de) | 2003-06-09 | 2004-06-02 | Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7767717B2 (enExample) |
| EP (1) | EP1631275B1 (enExample) |
| JP (1) | JP4682129B2 (enExample) |
| AT (1) | ATE393625T1 (enExample) |
| AU (1) | AU2004246812B8 (enExample) |
| CA (1) | CA2528431C (enExample) |
| DE (1) | DE602004013439T2 (enExample) |
| DK (1) | DK1631275T3 (enExample) |
| ES (1) | ES2304610T3 (enExample) |
| NZ (1) | NZ544031A (enExample) |
| PT (1) | PT1631275E (enExample) |
| WO (1) | WO2004110420A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4684655B2 (ja) | 2002-12-18 | 2011-05-18 | ラボラトワール ブザン アンテルナスィヨナル | ４−ヒドロキシタモキシフェンによる乳房密度低下 |
| PT1572178E (pt) * | 2002-12-18 | 2006-09-29 | Besins Int Lab | Tratamento de mastalgia com 4-hidroxi-tamoxifeno |
| EP1941871B1 (en) * | 2003-04-01 | 2014-01-08 | Besins Healthcare Luxembourg SARL | Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen |
| US7968532B2 (en) | 2003-12-15 | 2011-06-28 | Besins Healthcare Luxembourg | Treatment of gynecomastia with 4-hydroxy tamoxifen |
| CA2549824C (en) * | 2003-12-15 | 2012-03-13 | Laboratoires Besins International | Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia |
| EP1579857A1 (en) * | 2004-03-22 | 2005-09-28 | Laboratoires Besins International | Chemically stable compositions of 4-hydroxy tamoxifen |
| US7507769B2 (en) * | 2004-03-22 | 2009-03-24 | Laboratoires Besins International | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
| EP1647271A1 (en) * | 2004-10-14 | 2006-04-19 | Laboratoires Besins International | 4-Hydroxy tamoxifen gel formulations |
| EP1891945A1 (en) * | 2006-07-31 | 2008-02-27 | Laboratoires Besins International | Treatment and prevention of excessive scarring |
| CA2659344C (en) * | 2006-07-31 | 2015-03-17 | Laboratoires Besins International | Treatment and prevention of excessive scarring |
| AU2008343758A1 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars |
| AU2008343755A1 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin polynucleotides and peptides for the treatment ofabnormal or excessive scars |
| US20140350106A1 (en) * | 2013-05-22 | 2014-11-27 | Professional Compounding Centers Of America | Urea Silicone Gel for Scars and Hydration Treatment and Method of Using Same |
| US20140350117A1 (en) * | 2013-05-22 | 2014-11-27 | Professional Compounding Centers Of America | Topical Scar Treatment Composition and Method of Using Same |
| CN111163784B (zh) * | 2017-09-01 | 2024-07-26 | 黄玲惠 | 用于治疗蟹足肿的药物组合物及其用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2558373B1 (fr) * | 1984-01-20 | 1987-07-03 | Mauvais Jarvis Pierre | Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee |
| EP0287690B1 (de) | 1987-04-21 | 1992-09-02 | HEUMANN PHARMA GMBH & CO | Stabile Lösungsmitteladdukte von Z-1-(p-beta-Dimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl)-2-phenylbut-1-en |
| US5045553A (en) | 1987-06-24 | 1991-09-03 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter |
| DE3836862A1 (de) | 1988-10-27 | 1990-05-03 | Schering Ag | Mittel zur transdermalen applikation von steroidhormonen |
| JP3149180B2 (ja) * | 1989-07-31 | 2001-03-26 | マサチユセツツ・インスチチユート・オブ・テクノロジー | 瘢痕治療のためのカルシウム拮抗薬の使用 |
| TW218849B (enExample) | 1991-05-17 | 1994-01-11 | Bristol Myers Squibb Co | |
| DE69334068D1 (de) * | 1992-07-20 | 2006-11-16 | Massachusetts Inst Technology | Kontrolle der wundvernarbung mit calmodulin-inhibitoren oder protein-kinase-c-inhibitoren |
| US5552162A (en) * | 1993-02-09 | 1996-09-03 | Arch Development Corporation | Method for improvement of scar size and appearance |
| US5613958A (en) | 1993-05-12 | 1997-03-25 | Pp Holdings Inc. | Transdermal delivery systems for the modulated administration of drugs |
| US5720963A (en) | 1994-08-26 | 1998-02-24 | Mary Kay Inc. | Barrier disruption treatments for structurally deteriorated skin |
| AU2513899A (en) * | 1997-12-23 | 1999-07-19 | Hexal Ag | Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin |
| US6013270A (en) | 1998-04-20 | 2000-01-11 | The Procter & Gamble Company | Skin care kit |
| DE10033853A1 (de) | 2000-07-12 | 2002-01-31 | Hexal Ag | Transdermales therapeutisches System mit hochdispersem Siliziumdioxid |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| EP1317921B1 (fr) | 2001-12-07 | 2009-08-19 | Besins International Belgique | Composition pharmaceutique sous forme de gel ou de solution à base de dihydrotestostérone, son procédé de préparation et ses utilisations |
| JP4684655B2 (ja) | 2002-12-18 | 2011-05-18 | ラボラトワール ブザン アンテルナスィヨナル | ４−ヒドロキシタモキシフェンによる乳房密度低下 |
| PT1572178E (pt) | 2002-12-18 | 2006-09-29 | Besins Int Lab | Tratamento de mastalgia com 4-hidroxi-tamoxifeno |
| EP1941871B1 (en) | 2003-04-01 | 2014-01-08 | Besins Healthcare Luxembourg SARL | Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen |
| US7968532B2 (en) | 2003-12-15 | 2011-06-28 | Besins Healthcare Luxembourg | Treatment of gynecomastia with 4-hydroxy tamoxifen |
| EP1579856A1 (en) | 2004-03-22 | 2005-09-28 | Laboratoires Besins International | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
| EP1579857A1 (en) | 2004-03-22 | 2005-09-28 | Laboratoires Besins International | Chemically stable compositions of 4-hydroxy tamoxifen |
| US7507769B2 (en) | 2004-03-22 | 2009-03-24 | Laboratoires Besins International | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
| EP1647271A1 (en) | 2004-10-14 | 2006-04-19 | Laboratoires Besins International | 4-Hydroxy tamoxifen gel formulations |
-
2004
- 2004-06-02 AT AT04740032T patent/ATE393625T1/de active
- 2004-06-02 WO PCT/EP2004/006583 patent/WO2004110420A1/en not_active Ceased
- 2004-06-02 NZ NZ544031A patent/NZ544031A/en not_active IP Right Cessation
- 2004-06-02 EP EP04740032A patent/EP1631275B1/en not_active Expired - Lifetime
- 2004-06-02 DK DK04740032T patent/DK1631275T3/da active
- 2004-06-02 ES ES04740032T patent/ES2304610T3/es not_active Expired - Lifetime
- 2004-06-02 PT PT04740032T patent/PT1631275E/pt unknown
- 2004-06-02 JP JP2006515986A patent/JP4682129B2/ja not_active Expired - Lifetime
- 2004-06-02 US US10/858,399 patent/US7767717B2/en active Active
- 2004-06-02 DE DE602004013439T patent/DE602004013439T2/de not_active Expired - Lifetime
- 2004-06-02 AU AU2004246812A patent/AU2004246812B8/en not_active Expired
- 2004-06-02 CA CA2528431A patent/CA2528431C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004246812B8 (en) | 2010-01-14 |
| CA2528431C (en) | 2012-09-18 |
| WO2004110420A1 (en) | 2004-12-23 |
| HK1082203A1 (en) | 2006-06-02 |
| AU2004246812B2 (en) | 2009-12-17 |
| DE602004013439T2 (de) | 2009-06-04 |
| AU2004246812A1 (en) | 2004-12-23 |
| EP1631275B1 (en) | 2008-04-30 |
| PT1631275E (pt) | 2008-08-04 |
| DE602004013439D1 (de) | 2008-06-12 |
| DK1631275T3 (da) | 2008-08-18 |
| WO2004110420A8 (en) | 2005-11-24 |
| US20050032910A1 (en) | 2005-02-10 |
| JP2006527234A (ja) | 2006-11-30 |
| CA2528431A1 (en) | 2004-12-23 |
| ES2304610T3 (es) | 2008-10-16 |
| US7767717B2 (en) | 2010-08-03 |
| EP1631275A1 (en) | 2006-03-08 |
| NZ544031A (en) | 2008-08-29 |
| JP4682129B2 (ja) | 2011-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE393625T1 (de) | Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen | |
| ATE526959T1 (de) | Behandlung von muskelschwund mit selektiven androgenrezeptormodulatoren | |
| ATE316786T1 (de) | Behandlung von mukositis | |
| ATE457166T1 (de) | Orale zusammensetzungen zur behandlung von diabetes | |
| DE60101265D1 (de) | Behandlung von augenschmerzen | |
| ATE460164T1 (de) | Mittel zur behandlung von hyperlipidämie mit pitavastatinen und eicosapentaensäure | |
| DE502005010615D1 (de) | Mittel zur behandlung von entzündlichen erkrankungen | |
| ATE376828T1 (de) | Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms | |
| ATE412646T1 (de) | Zur behandlung von schmerzen geeignete therapeutische mittel | |
| BR0312597A (pt) | Combinações de drogas para o tratamento de neoplasmas | |
| DE602004022285D1 (de) | Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika | |
| DE60212613D1 (de) | Doxycyclin zur behandlung von akne | |
| DE602004011051D1 (de) | Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten | |
| CY1110369T1 (el) | Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη | |
| EA200702212A1 (ru) | Способ лечения или профилактики разрушения кости или остеопороза | |
| ATE359808T1 (de) | Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma | |
| ATE344662T1 (de) | Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen | |
| ATE382354T1 (de) | Präoperative behandlung von postoperativen schmerzen | |
| ATE406171T1 (de) | Aplidine zur behandlung von multiplem myelom | |
| EP1056458A4 (en) | PROCESS FOR THE TREATMENT OF PAIN, ESPECIALLY CHRONIC PAIN SPECIFIC TO WOMEN | |
| EA200600989A1 (ru) | Применение габоксадола для лечения бессонницы | |
| DE60335093D1 (de) | Verwendung von nichtantibakteriellen tetrazyklin-analoga und ihren formulierungen für die behandlung von bakteriellen exotoxinen | |
| ATE315387T1 (de) | Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz | |
| DE60231994D1 (de) | Mittel zur behandlung oder prävention allergischerg | |
| DE60334289D1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1631275 Country of ref document: EP |